BY AND BETWEEN
(d.b.a. HYSEQ PHARMACEUTICALS)
JANUARY 8, 2002
THIS COLLABORATION AGREEMENT (the "Agreement") is made effective as of January 8, 2002 (the
"Effective Date") by and between AMGEN INC., a Delaware corporation having its principal place of business
at One Amgen Center Drive, Thousand Oaks, California 91320-1799 ("Amgen") and HYSEQ, INC., d.b.a.
HYSEQ PHARMACEUTICALS, a Nevada corporation having its principal place of business at 670 Almanor
Avenue, Sunnyvale, California 94085-1710 ("Hyseq"). Amgen and Hyseq are sometimes referred to herein
individually as a "Party" and collectively as the "Parties".
WHEREAS, Amgen has developed certain technology and know-how which relates to a protein known as
WHEREAS, Hyseq has technology and know-how and significant experience and expertise in the research and
development of pharmaceutical products that may be particularly well suited to develop and market a product
such as Alfimeprase;
WHEREAS, Hyseq now wishes to collaborate with Amgen in the further research, development and
commercialization of Alfimeprase on the terms and conditions set forth herein;
WHEREAS, the Parties believe it to be in their mutual interest to combine their mutual experience, know-how
and expertise and to grant each other such intellectual property licenses and other rights as are necessary to
diligently continue the research and development begun by Amgen so as to commercialize Alfimeprase or one or
more products resulting from the aforesaid continuing research and development.
NOW THEREFORE, based on the foregoing premises and the mutual covenants and obligations set forth below,
the Parties agree as follows:
Capitalized terms used but not otherwise defined herein have the meanings provided in EXHIBIT A hereto.
2.1 COLLABORATION. The Parties agree to jointly Develop a